🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

Published 09/10/2024, 04:23 PM
Updated 09/10/2024, 05:31 PM
© Reuters. FILE PHOTO: People walk by a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File Photo
TEVA
-
CAH
-
MCK
-
JNJ
-
CVS
-
WBA
-
ABBV
-

By Brendan Pierson

(Reuters) - Baltimore said on Tuesday that it has settled with Walgreens over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.

The announcement came a day after the city reached an $80 million settlement over opioids with drugmaker Teva Pharmaceutical (NYSE:TEVA). Baltimore did not disclose the terms of its settlement with Walgreens, but the cumulative settlement amount implies that it was also $80 million.

"We are proud of our efforts to bring these companies to justice over the past several years," Baltimore Mayor Brandon Scott said in a statement.

Walgreens said in a statement: "Although Walgreens strongly disputes any liability, this settlement is in the best interests of all of our stakeholders."

The remaining defendants scheduled to face trial next week are drugmaker Johnson & Johnson (NYSE:JNJ), and distributors McKesson (NYSE:MCK) and Cencora.

"We will challenge the city's claims - which have no basis in the facts or the law," J&J said in a statement, adding that it "did everything a responsible manufacturer of these important prescription pain medicines should do."

Teva, McKesson and Cencora did not immediately respond to requests for comment.

Baltimore earlier this year announced settlements with drugmaker AbbVie (NYSE:ABBV)'s Allergan (NYSE:AGN) unit, pharmacy operator CVS and drug distributor Cardinal Health (NYSE:CAH).

Like more than 3,000 other local governments that have filed lawsuits over opioids, the city accused drugmakers of downplaying opioids' addiction risks, and distributors and pharmacies of ignoring red flags that pills were being diverted into illegal channels.

The vast majority of those cases have been settled through nationwide agreements, which now total about $46 billion.

© Reuters. FILE PHOTO: People walk by a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File Photo

Baltimore opted against joining those global settlements in the hopes of recovering more than it would have received through those deals. The city said that under a multi-state settlement with Teva, for example, it would have received only $11 million over 13 years.

More than 800,000 people in the United States died of opioid overdoses from 1999 through 2023, according to data from the U.S. Centers for Disease Control and Prevention.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.